Service agreements signed between TKT and Karolinska Development

It is with pleasure that Toxicology Knowledge Team Sweden AB (TKT) announce that TKT and Karolinska Development ( ) have signed a joint Service Agreement. The agreement provides Karolinska Development portfolio companies with fast and direct access to TKT’s toxicological expertise.TKT offers tailored toxicological project support in all areas of drug development.

– We adjust our long experience from big pharma to the conditions in smaller biotech companies. Our goal is that Karolinska Development portfolio companies should be able to use TKT as their own internal experts, says Kerstin Kenne, CEO of TKT.

TKT will also, through seminars and workshops, strive to increase the knowledge and awareness of toxicology and its implementation in all areas of the drug development process.

– With this agreement, Karolinska Development wishes to faciltate access to TKT’s experience and expertise in toxicology for our portfolio companies. The aim is to achieve greater efficiency in the development process, making it easier for companies to achieve their goals of developing clearly differentiated pharmaceutical products to meet unmet medical needs, says Gunilla Ekstrom, VP Operations, Karolinska Development AB.